Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02536755
Registration number
NCT02536755
Ethics application status
Date submitted
27/08/2015
Date registered
1/09/2015
Date last updated
15/07/2022
Titles & IDs
Public title
Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies
Query!
Scientific title
Open Label Interventional Multicenter Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Successfully Completed the Phase 2 or Phase 3 Studies
Query!
Secondary ID [1]
0
0
U1111-1166-6190
Query!
Secondary ID [2]
0
0
EFC13781
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
EXOSKEL
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Gaucher Disease
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Eliglustat, GZ385660
Experimental: Eliglustat - Participants who completed one of the Phase 2 (GZGD00304 [NCT00358150]) or Phase 3 studies (GZGD02507 [NCT00891202], GZGD02607 [NCT00943111], or GZGD03109 [NCT01074944]) were enrolled in this current (EFC13781) study. Participants who were cytochrome P450 (CYP) 2D6 intermediate metabolizer (IM), extensive metabolizer (EM) and ultra-rapid metabolizers (URM) received eliglustat 84 milligrams (mg) twice daily and participants who were CYP2D6 poor metabolizer (PM) received eliglustat 84 mg once daily, for duration of minimum 2 years (unless early discontinuation occurred) and up to 4 years, or until commercial eliglustat was available to participants through reimbursement or through the compassionate use (expanded access) program.
Treatment: Drugs: Eliglustat, GZ385660
Pharmaceutical form: capsule
Route of administration: oral
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Mobility Status Assessments at Study Baseline, Weeks 52, 104, 156 and 208
Query!
Assessment method [1]
0
0
Mobility, i.e., ability to walk was assessed as a part of Gaucher disease assessment in participants. In this outcome measure, number of participants with their different mobility status along with the use of mobility aids (unrestricted mobility, walks with difficulty, walks with orthopaedic aid, requires wheelchair, bedridden) at specified time points were reported. Baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [1]
0
0
Study Baseline, Weeks 52, 104, 156 and 208
Query!
Primary outcome [2]
0
0
Number of Participants With Bone Pain Levels During the Past 4 Weeks at Study Baseline, Weeks 52, 104, 156 and 208
Query!
Assessment method [2]
0
0
Bone pain was assessed as a part of Gaucher disease assessment in participants. Participants were categorized as none (no bone pain), very mild bone pain, mild bone pain, moderate bone pain, severe bone pain and extreme bone pain during the past 4 weeks at each specified visit. In this outcome measure, number of participants with different level of bone pain during the past 4 weeks at specified time points were reported. Baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [2]
0
0
Study Baseline, Weeks 52, 104, 156 and 208
Query!
Primary outcome [3]
0
0
Number of Participants With Bone Crisis at Study Baseline, Weeks 52, 104, 156 and 208
Query!
Assessment method [3]
0
0
Bone crisis was assessed as a part of Gaucher disease assessment in participants. Acute, excruciating episodic bone pain is characteristic of Gaucher bone crisis, which typically causes periosteal elevation, elevated white blood cell count, fever, or debilitation lasting several days or longer and requires treatment with immobilization of the affected area, and opioid analgesics. Participants were categorized as 0= no bone crisis, 1= 1 bone crisis, 2= 2 bone crisis and >=3 = more than 3 bone crisis during the assessment period. In this outcome measure, number of participants with different bone crises levels at specified time points were reported. Baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [3]
0
0
Study Baseline, Weeks 52, 104, 156 and 208
Query!
Primary outcome [4]
0
0
Change From Current Study Baseline in Total Bone Marrow Burden (BMB) Scores at Weeks 52, 104, 156 and 208
Query!
Assessment method [4]
0
0
Bone marrow burden (BMB) scores indicate the degree of bone marrow infiltration. BMB score was measured using MRI (magnetic resonance imaging (MRI), ranged from 0 (no abnormalities) to 8 points (severe disease) for the lumbar spine and from 0 (no abnormalities) to 8 points (severe disease) for the femurs. The total BMB score was calculated as the sum of scores for femur and lumbar spine regions which ranged from 0 (no abnormalities) to 16 (severe disease) points. A higher BMB score signified more severe bone marrow involvement. For this outcome measure, baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [4]
0
0
Study Baseline, Weeks 52, 104, 156 and 208
Query!
Primary outcome [5]
0
0
Change From Eliglustat Baseline in Total Bone Marrow Burden (BMB) Scores at Weeks 52, 104, 156 and 208
Query!
Assessment method [5]
0
0
Bone marrow burden (BMB) scores indicate the degree of bone marrow infiltration was measured using MRI, ranged from 0 (no abnormalities) to 8 points (severe disease) for the lumbar spine and from 0 (no abnormalities) to 8 points (severe disease) for the femurs. The total BMB score was calculated as the sum of scores for femur and lumbar spine regions which ranged from 0 (no abnormalities) to 16 (severe disease) points. A higher BMB score signified more severe bone marrow involvement. For this outcome measure, baseline refers to the eliglustat baseline, which was defined as participant's status at the time of first dose of eliglustat in the previous Phase 2 or Phase 3 study.
Query!
Timepoint [5]
0
0
Eliglustat Baseline, Weeks 52, 104, 156 and 208 of the current study
Query!
Primary outcome [6]
0
0
Change From Current Study Baseline in Total Spine and Femur Bone Mineral Density (BMD) at Weeks 52, 104, 156 and 208
Query!
Assessment method [6]
0
0
Bone Mineral Density (BMD) measurements of the spine and bilateral femur were acquired by dual energy X-Ray absorptiometry (DXA) scan. Worst total femur at Baseline refers to the "worst" diseased left or right femur at Baseline. For this outcome measure, baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [6]
0
0
Study Baseline, Weeks 52, 104, 156 and 208
Query!
Primary outcome [7]
0
0
Change From Eliglustat Baseline in Total Spine and Femur Bone Mineral Density (BMD) at Weeks 52, 104, 156 and 208
Query!
Assessment method [7]
0
0
BMD measurements of the spine and bilateral femur were acquired by DXA scan. Worst total femur at Baseline refers to the "worst" diseased left or right femur at baseline. For this outcome measure, baseline refers to the eliglustat baseline, which was defined as participant's status at the time of first dose of eliglustat in the previous Phase 2 or Phase 3 study.
Query!
Timepoint [7]
0
0
Eliglustat Baseline, Weeks 52, 104, 156 and 208 of the current study
Query!
Primary outcome [8]
0
0
Change From Current Study Baseline in Spine and Femur Total T-Scores for BMD at Weeks 52, 104, 156 and 208
Query!
Assessment method [8]
0
0
BMD measurements of the spine and bilateral femur were acquired by DXA scan. The T-score bone density categories were: normal (score >-1), osteopenia (score -2.5 to <=-1), and osteoporosis (score <= -2.5). Worst total femur at Baseline refers to the "worst" diseased left or right femur at baseline. For this outcome measure, baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [8]
0
0
Study Baseline, Weeks 52, 104, 156 and 208
Query!
Primary outcome [9]
0
0
Change From Eliglustat Baseline in Spine and Femur Total T-Scores for BMD at Weeks 52, 104, 156 and 208
Query!
Assessment method [9]
0
0
BMD measurements of the spine and bilateral femur were acquired by DXA scan. The T-score bone density categories were: normal (score >-1), osteopenia (score -2.5 to <=-1), and osteoporosis (score <= -2.5). Worst total femur at Baseline refers to the "worst" diseased left or right femur at baseline. For this outcome measure, baseline refers to the eliglustat baseline, which was defined as participant's status at the time of first dose of eliglustat in the previous Phase 2 or Phase 3 study.
Query!
Timepoint [9]
0
0
Eliglustat Baseline, Weeks 52, 104, 156 and 208 of the current study
Query!
Primary outcome [10]
0
0
Change From Current Study Baseline in Spine and Femur Total Z-Scores for BMD at Weeks 52, 104, 156 and 208
Query!
Assessment method [10]
0
0
BMD measurements of the spine and bilateral femur were acquired by DXA scan. The Z-score bone density categories were: normal (score >-2) and below normal (score <=-2). Worst total femur at Baseline refers to the "worst" diseased left or right femur at baseline. For this outcome measure, baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [10]
0
0
Study Baseline, Weeks 52, 104, 156 and 208
Query!
Primary outcome [11]
0
0
Change From Eliglustat Baseline in Spine and Femur Total Z-Scores for BMD at Weeks 52, 104, 156 and 208
Query!
Assessment method [11]
0
0
BMD measurements of the spine and bilateral femur were acquired by DXA scan. The Z-score bone density categories are: normal (score >-2) and below normal (score <=-2). Worst total femur at Baseline refers to the "worst" diseased left or right femur at baseline. For this outcome measure, baseline refers to the eliglustat baseline, which was defined as participant's status at the time of first dose of eliglustat in the previous Phase 2 or Phase 3 study.
Query!
Timepoint [11]
0
0
Eliglustat Baseline, Weeks 52, 104, 156 and 208 of the current study
Query!
Primary outcome [12]
0
0
Total Number of New or Worsening Osteonecrosis Events for Spine and Femur at Study Baseline, Week 52, 104, 156 and 208
Query!
Assessment method [12]
0
0
Osteonecrosis was assessed by bone MRI and X-Ray for spine and by MRI for femur. Total number of new or worsening osteonecrosis events among all the participants with corresponding assessment at specified time points were reported in this outcome measure. For this outcome measure, baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [12]
0
0
Study Baseline, Weeks 52, 104, 156 and 208
Query!
Primary outcome [13]
0
0
Total Number of New or Worsening Fracture Events for Spine and Femur at Study Baseline, Week 52, 104, 156 and 208
Query!
Assessment method [13]
0
0
Fracture was assessed by bone MRI and X-Ray for spine and by MRI for femur. Total number of new or worsening fracture events among all the participants with corresponding assessment at specified time points were reported in this outcome measure. For this outcome measure, baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [13]
0
0
Study Baseline, Weeks 52, 104, 156 and 208
Query!
Primary outcome [14]
0
0
Total Number of New or Worsening Infarcts Events for Spine and Femur at Study Baseline, Week 52, 104, 156 and 208
Query!
Assessment method [14]
0
0
Infarcts were assessed by bone MRI and X-Ray for spine and by MRI for femur. Total number of new or worsening infarcts events among all the participants with corresponding assessment at specified time points were reported in this outcome measure. For this outcome measure, baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [14]
0
0
Study Baseline, Weeks 52, 104, 156 and 208
Query!
Primary outcome [15]
0
0
Total Number of New or Worsening Lytic Lesions Events for Spine at Study Baseline, Week 104, and 208
Query!
Assessment method [15]
0
0
Lytic Lesions were assessed by bone X-Ray for spine. Total number of new or worsening lytic lesions events among all the participants with corresponding assessment at specified time points were reported in this outcome measure. For this outcome measure, baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [15]
0
0
Study Baseline, Weeks 104, and 208
Query!
Primary outcome [16]
0
0
Observed Annual Incidence Rate for Spine and Femur Osteonecrosis at Week 52, 104, 156 and 208
Query!
Assessment method [16]
0
0
Observed annual incidence rate was estimated using the total number of events divided by the total years of follow-up in each specified year (for all participants). Osteonecrosis was assessed by bone MRI and X-Ray for spine and by MRI for femur.
Query!
Timepoint [16]
0
0
For 52 Weeks (i.e., 1 year),104 Weeks (i.e., 2 year), 156 Weeks (i.e., 3 year) and 208 Weeks (i.e., 4 years)
Query!
Primary outcome [17]
0
0
Observed Annual Incidence Rate for Spine and Femur Fracture at Week 52, 104, 156 and 208
Query!
Assessment method [17]
0
0
Observed annual incidence rate was estimated using the total number of events divided by the total years of follow-up in each specified year (for all participants). Fracture was assessed by bone MRI and X-Ray for spine and by MRI for femur.
Query!
Timepoint [17]
0
0
For 52 Weeks (i.e., 1 year),104 Weeks (i.e., 2 year), 156 Weeks (i.e., 3 year) and 208 Weeks (i.e., 4 years)
Query!
Primary outcome [18]
0
0
Observed Annual Incidence Rate for Spine and Femur Infarcts at Week 52, 104, 156 and 208
Query!
Assessment method [18]
0
0
Observed annual incidence rate was estimated using the total number of events divided by the total years of follow-up in each specified year (for all participants). Infarcts were assessed by bone MRI and X-Ray for spine and by MRI for femur.
Query!
Timepoint [18]
0
0
For 52 Weeks (i.e., 1 year),104 Weeks (i.e., 2 year), 156 Weeks (i.e., 3 year) and 208 Weeks (i.e., 4 years)
Query!
Primary outcome [19]
0
0
Observed Annual Incidence Rate for Spine Lytic Lesion at Week 104, and 208
Query!
Assessment method [19]
0
0
Observed annual incidence rate was estimated using the total number of events divided by the total years of follow-up in each specified year (for all participants). Lytic Lesions were assessed by bone X-Ray for spine.
Query!
Timepoint [19]
0
0
For 104 Weeks (i.e., 2 year), and 208 Weeks (i.e., 4 years)
Query!
Primary outcome [20]
0
0
Change From Current Study Baseline in Bone Biomarker Level: Macrophage Inflammatory Protein 1 Beta (MIP-1ß) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234
Query!
Assessment method [20]
0
0
MIP-1ß considered a biomarker of active bone disease, was assayed from plasma. For this outcome measure, baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [20]
0
0
Study Baseline, Weeks 26, 52, 78, 104, 130, 156, 182, 208 and 234
Query!
Primary outcome [21]
0
0
Change From Eliglustat Baseline in Bone Biomarker Level: Macrophage Inflammatory Protein 1 Beta (MIP-1ß) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234
Query!
Assessment method [21]
0
0
MIP-1ß considered a biomarker of active bone disease, was assayed from plasma. For this outcome measure, baseline refers to the eliglustat baseline, which was defined as participant's status at the time of first dose of eliglustat in the previous Phase 2 or Phase 3 study.
Query!
Timepoint [21]
0
0
Eliglustat Baseline, Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234 of the current study
Query!
Primary outcome [22]
0
0
Change From Current Study Baseline in Bone Biomarker Level: Procollagen 1 N- Terminal Propeptide (P1NP) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234
Query!
Assessment method [22]
0
0
P1NP, a marker of bone formation was assayed from plasma. For this outcome measure, baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [22]
0
0
Study Baseline, Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234
Query!
Primary outcome [23]
0
0
Change From Eliglustat Baseline in Bone Biomarker Level: Procollagen 1 N- Terminal Propeptide (P1NP) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234
Query!
Assessment method [23]
0
0
P1NP, a marker of bone formation was assayed from plasma. For this outcome measure, baseline refers to the eliglustat baseline, which was defined as participant's status at the time of first dose of eliglustat in the previous Phase 2 or Phase 3 study.
Query!
Timepoint [23]
0
0
Eliglustat Baseline, Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234 of the current study
Query!
Primary outcome [24]
0
0
Change From Current Study Baseline in Bone Biomarker Level: Type 1 Collagen C-Telopeptides (CTx) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234
Query!
Assessment method [24]
0
0
CTx, a marker of bone resorption was assayed from plasma. For this outcome measure, baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [24]
0
0
Study Baseline, Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234
Query!
Primary outcome [25]
0
0
Change From Eliglustat Baseline in Bone Biomarker Level: Type 1 Collagen C-Telopeptides (CTx) at Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234
Query!
Assessment method [25]
0
0
CTx, a marker of bone resorption was assayed from plasma. For this outcome measure, baseline refers to the eliglustat baseline, which was defined as participant's status at the time of first dose of eliglustat in the previous Phase 2 or Phase 3 study.
Query!
Timepoint [25]
0
0
Eliglustat Baseline, Weeks 26, 52, 78, 104, 130, 156,182, 208 and 234 of the current study
Query!
Secondary outcome [1]
0
0
Change From Current Study Baseline in Gaucher Disease Type 1 (GD1) Biomarker Levels: Chitotriosidase at Week 26, 52, 78, 104, 130, 156, 182, 208 and 234
Query!
Assessment method [1]
0
0
Chitotriosidase biomarker was assayed from plasma. Chitotriosidase biomarker levels for participants who were CYP2D6 non-Ultra Rapid Metabolizers (non-URM) was reported in this outcome measure. For this outcome measure, baseline refers to the study baseline, which was defined as status at study entry.
Query!
Timepoint [1]
0
0
Study Baseline, Week 26, 52, 78, 104, 130, 156, 182, 208 and 234
Query!
Secondary outcome [2]
0
0
Change From Eliglustat Baseline in Gaucher Disease Type 1 (GD1) Biomarker Levels: Chitotriosidase at Week 26, 52, 78, 104, 130, 156, 182, 208 and 234
Query!
Assessment method [2]
0
0
Chitotriosidase biomarker was assayed from plasma. Chitotriosidase biomarker levels for participants who were CYP2D6 non-URM was reported in this outcome measure. For this outcome measure, baseline refers to the eliglustat baseline, which was defined as participant's status at the time of first dose of eliglustat in the previous Phase 2 or Phase 3 study. Data for this outcome measure was planned to be collected and analyzed in reference to eliglustat baseline separately for Phase 2, ENGAGE and EDGE studies (GD treatment naïve participants) and from ENCORE study (participants switched from ERT).
Query!
Timepoint [2]
0
0
Eliglustat Baseline, Week 26, 52, 78, 104, 130, 156, 182, 208 and 234 of the current study
Query!
Secondary outcome [3]
0
0
Change From Current Study Baseline in GD1 Biomarker Levels: Glucosylceramide (GL-1) at Week 26, 52, 78, 104, 130, 156, 182, 208 and 234
Query!
Assessment method [3]
0
0
Glucosylceramide (GL-1) biomarker was assayed from plasma. GL-1 biomarker levels for participants who were CYP2D6 non-URM was reported in this outcome measure. For this outcome measure, baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [3]
0
0
Study Baseline, Week 26, 52, 78, 104, 130, 156, 182, 208 and 234
Query!
Secondary outcome [4]
0
0
Change From Eliglustat Baseline in GD1 Biomarker Levels: Glucosylceramide (GL-1) at Week 26, 52, 78, 104, 130, 156, 182, 208 and 234
Query!
Assessment method [4]
0
0
Glucosylceramide (GL-1) biomarker was assayed from plasma. GL-1 biomarker levels for participants who were CYP2D6 non-URM was reported in this outcome measure. For this outcome measure, baseline refers to the eliglustat baseline, which was defined as participant's status at the time of first dose of eliglustat in the previous Phase 2 or Phase 3 study. Data for this outcome measure was planned to be collected and analyzed in reference to eliglustat baseline separately for participants from Phase 2, ENGAGE and EDGE studies (GD treatment naïve participants) and from ENCORE study (participants switched from ERT).
Query!
Timepoint [4]
0
0
Eliglustat Baseline, Week 26, 52, 78, 104, 130, 156, 182, 208 and 234 of the current study
Query!
Secondary outcome [5]
0
0
Change From Current Study Baseline in GD1 Biomarker Levels: Lyso Glucosylceramide (Lyso-GL-1) at Week 26, 52, 78, 104, 130, 156, 182, 208 and 234
Query!
Assessment method [5]
0
0
Lyso-GL-1 biomarker was assayed from plasma. Lyso-GL-1 biomarker levels for participants who were CYP2D6 non-URM was reported in this outcome measure. For this outcome measure, baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [5]
0
0
Study Baseline, Week 26, 52, 78, 104, 130, 156, 182, 208 and 234
Query!
Secondary outcome [6]
0
0
Change From Eliglustat Baseline in GD1 Biomarker Levels: Lyso Glucosylceramide (Lyso-GL-1) at Week 26, 52, 78, 104, 130, 156, 182, 208 and 234
Query!
Assessment method [6]
0
0
Lyso-GL-1 biomarker was assayed from plasma. Lyso-GL-1 biomarker levels for participants who were CYP2D6 non-URM was reported in this outcome measure. For this outcome measure, baseline refers to the eliglustat baseline, which was defined as participant's status at the time of first dose of eliglustat in the previous Phase 2 or Phase 3 study. Data for this outcome measure was planned to be collected and analyzed in reference to eliglustat baseline separately for participants from Phase 2, ENGAGE and EDGE studies (GD treatment naïve participants) and from ENCORE study (participants switched from ERT).
Query!
Timepoint [6]
0
0
Eliglustat Baseline, Week 26, 52, 78, 104, 130, 156, 182, 208 and 234 of the current study
Query!
Secondary outcome [7]
0
0
Change From Current Study Baseline in Short Form-36 Health Survey (SF-36) Scores at Weeks 26, 52, 78, 104, 130, 156, 182, 208 and 234
Query!
Assessment method [7]
0
0
The 36-Item Short-Form Health Survey (SF-36) is standardized survey evaluating 8 aspects of functional health and well-being. Physical Component Summary (PCS) with 4 sub-scales: physical function, role limitations due to physical problems, bodily pain, and general health perception; and Mental Component Summary (MCS) with 4 sub-scales: vitality, social function, role limitations due to emotional problems, and mental health. Summations of item scores of the same sub-scale give the sub-scale scores, which are transformed into a range from 0 to 100; 0= worst and 100=best outcome. Both PCS and MCS range from 0 to 100 with higher scores indicating better physical and mental health. For this outcome measure, baseline refers to the current study baseline, which was defined as status at this study (EFC13781) entry.
Query!
Timepoint [7]
0
0
Study Baseline, Weeks 26, 52, 78, 104, 130, 156, 182, 208 and 234
Query!
Secondary outcome [8]
0
0
Change From Eliglustat Baseline in SF-36 Scores at Weeks 26, 52, 78, 104, 130, 156, 182, 208 and 234
Query!
Assessment method [8]
0
0
SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being. PCS with 4 sub-scales: physical function, role limitations due to physical problems, pain, and general health perception; and MCS with 4 sub-scales: vitality, social function, role limitations due to emotional problems, and mental health. Summations of item scores of same sub-scale give the sub-scale scores, which are transformed into range from 0 to 100; 0= worst, and 100=best outcome. Both PCS and MCS range from 0 to 100, higher scores indicating better physical and mental health. For this outcome measure, baseline refers to the eliglustat baseline, which was defined as participant's status at the time of first dose of eliglustat in the previous Phase 2 or Phase 3 study.
Query!
Timepoint [8]
0
0
Eliglustat Baseline, Weeks 26, 52, 78, 104, 130, 156, 182, 208 and 234 of the current study
Query!
Secondary outcome [9]
0
0
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Query!
Assessment method [9]
0
0
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. A serious adverse event (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the treatment-emergent period (time from the first administration of the investigational medicinal product (IMP) to the last administration of the IMP + 5 days).
Query!
Timepoint [9]
0
0
From the first administration of the IMP to the last administration of the IMP + 5 days (up to 4 years, or until commercial eliglustat was available to participants through reimbursement or through the compassionate use [expanded access] program)
Query!
Eligibility
Key inclusion criteria
Inclusion criteria :
- The participant must have successfully completed the Phase 2 (GZGD00304) or a Phase 3
study (GZGD02507, GZGD02607 or GZGD03109). Successful completion was defined as
participants enrolled in one of the above mentioned studies who received eliglustat
through the end of the study and completed the end-of-study visit without having
discontinued or been withdrawn prematurely.
- The participant was willing and able to provide signed informed consent prior to any
protocol-required procedures being performed.
- Female participants of childbearing potential must have had a documented negative
pregnancy test prior to enrollment and while they were receiving eliglustat treatment.
- Female participants of childbearing potential must have been willing to practice true
abstinence in line with their preferred and usual lifestyle, or used a medically
accepted form of contraception (either a barrier method, such as condom or diaphragm +
spermicide, or a non-barrier method such as oral, injected, or implanted hormonal
methods, or an intra-uterine device or system) while receiving eliglustat.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- The participant was unwilling to comply with the requirements of the protocol.
- The participant had received an investigational product (other than eliglustat) within
30 days prior to enrollment.
- The participant had received miglustat within the 6 months prior to enrollment.
- The participant had documented prior esophageal varices or liver infarction or current
liver enzymes (alanine transaminase, aspartate aminotransferase) or total bilirubin
greater than (>)2 times the upper limit of normal, unless the participant had a
diagnosis of Gilbert Syndrome.
- The participant had any clinically significant disease, other than Gaucher disease,
including cardiovascular, renal, hepatic, gastrointestinal, pulmonary, neurologic,
endocrine, metabolic (eg, hypokalemia, hypomagnesemia), or psychiatric disease, other
medical conditions, or serious intercurrent illnesses that might preclude
participation in the study.
- The participant was known to have any of the following: cardiac disease (congestive
heart failure, recent acute myocardial infarction, bradycardia, heart block,
ventricular arrhythmia), long QT syndrome, or current treatment with Class IA or Class
III antiarrhythmic medicinal products.
- The participant had tested positive for the human immunodeficiency virus antibody,
hepatitis C antibody, or hepatitis B surface antigen.
- The participant had a history of cancer within 6 months of enrolment, with the
exception of basal cell carcinoma.
- Participant was a CYP2D6 IM, EM or URM and was taking a strong or moderate CYP2D6
inhibitor concomitantly with a strong or moderate CYP3A inhibitor.
- Participant was a CYP2D6 PM having taken a strong CYP3A inhibitor within 2 weeks prior
to enrolment.
- If a female participant of childbearing potential had a positive pregnancy test (blood
ß-human chorionic gonadotropin [ß-HCG]) or was breastfeeding prior to first dosing of
eliglustat in this study, the participant could not enroll in the study at that time,
but might have been rescreened after the end of the pregnancy, and/or when she was no
longer breast feeding, provided rescreening took place before the end of the
enrollment period.
- Women of childbearing potential who were unwilling or unable to be tested for
pregnancy.
The above information was not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/10/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
24/06/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
31
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
Canada
Query!
State/province [1]
0
0
Montreal
Query!
Country [2]
0
0
Russian Federation
Query!
State/province [2]
0
0
Moscow
Query!
Country [3]
0
0
Russian Federation
Query!
State/province [3]
0
0
St-Petersburg
Query!
Country [4]
0
0
Tunisia
Query!
State/province [4]
0
0
Tunis
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Genzyme, a Sanofi Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Primary Objective:
Evaluate long term skeletal response to eliglustat in adult participants who successfully
completed one of the Phase 2 or Phase 3 eliglustat studies.
Secondary Objective:
Evaluate the safety of eliglustat (by serious adverse event continuous monitoring), the
quality of life (Short Form-36 Health Survey [SF-36]) and biomarkers of Gaucher disease type
1 (GD1) (chitotriosidase, plasma glucosylceramide [GL-1] and lyso glucosylceramide
[lyso-GL-1]) in adult participants who successfully completed one of the Phase 2 or Phase 3
studies.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02536755
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Clinical Sciences & Operations
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02536755
Download to PDF